Product
GSK4172239D
1 clinical trial
3 indications
Indication
Hematologic DisordersIndication
AnemiaIndication
Sickle CellClinical trial
A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Parallel Group, Single Dose, Dose Escalation Phase I Study in Sickle Cell Disease Participants, to Evaluate the Safety, Tolerability, and Pharmacokinetics of GSK4172239DStatus: Recruiting, Estimated PCD: 2025-03-11